Clinical trials / NCT06328777
NCT06328777Phase 2, phase 3Recruiting

RESET-SSc: An Open-Label Study to Evaluate the Safety and Efficacy of CABA-201, a CD19-CAR T Cell Therapy, in Subjects With Systemic Sclerosis

Study sponsor: Cabaletta Bio

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov recordCSV export · Pro
Primary completion2029-07Estimated
Enrollment · participants37Estimated
Source updated2026-08-17Last update listed in the registry record
Version history

Changes to this trial

Last 12 months
Pro unlocks the full available history and CSV export. View Pro features

· 3 fields changed

Main study measure wording changed

Text changed; whether the study measures changed has not been verified. Saved text may be shortened.

Compare wording
− Before

Measure: To evaluate incidence of adverse events

+ After

Measure: Phase 1/2: To evaluate incidence of adverse events Measure: Phase 2b Sub-study: To evaluate the efficacy of CABA-201 on % predicted forced vital capacity (FVC) in SSc-ILD subjects

Planned enrollment increased by 25 participants

− Before

12 participants (planned)

+ After

37 participants (planned)

Phase changed

− Before

PHASE1, PHASE2

+ After

PHASE2, PHASE3

Check registry source